Filing identity and reporting period
Important issuer mismatch: The supplied filing is for Original Source Entertainment, Inc., not NEUROONE MEDICAL TECHNOLOGIES Corp. It is a Form 10-K for the fiscal year ended December 31, 2014, rather than a quarterly filing. The summary below reflects the filing’s stated issuer and period.
Business context
Original Source describes itself as a development-stage music licensing business, offering songs for use in television and film. It reported a catalog of more than 1,100 songs and contracts with approximately 217 artist-composers. The company had no employees other than its officers, and its operations remained limited. Historically, Warner Bros. accounted for about 90% of revenue, though the filing does not specify customer concentration for 2014.
Financial results and liquidity
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | $773 | $1,249 |
| Operating expenses | $36,687 | $26,342 |
| Net loss | $36,244 | $30,554 |
| Net cash used in operating activities | $26,173 | $25,093 |
| Cash at year-end | $205 | $525 |
Revenue declined about 38%, while the net loss increased about 19%. The 2014 net loss was approximately 47 times revenue; the filing provides no gross profit or gross margin measure. There was no investing cash flow in either year. Financing provided $25,853 in 2014, including $22,628 of related-party advances and $3,225 from a convertible note. The balance sheet reported total current liabilities of $35,594, total assets of $205, and a working-capital deficit of $35,389. The year-end balance sheet showed no notes payable, but included $22,628 in related-party advances.
Material changes, outlook and risks
- General and administrative expenses rose by $10,345, primarily reflecting legal, accounting and audit costs associated with public-company reporting.
- Related parties forgave liabilities totaling $28,146 in 2014; the forgiveness was recorded in additional paid-in capital.
- Management expects continuing losses and negative operating cash flow and says additional debt or equity financing will be needed. It gave no quantified revenue or earnings guidance and cannot assure financing will be available on acceptable terms.
- The auditor’s report and management’s discussion identify substantial doubt about the company’s ability to continue as a going concern. The statements contain no adjustments for the possible outcome.
- Disclosure controls and internal control over financial reporting were deemed ineffective, with a material weakness attributed to resource constraints and inadequate segregation of duties. Management described recruiting experienced professionals as a possible corrective step, without assurance it would be sufficient.
- The filing describes intense competition, dependence on obtaining financing and very limited revenue. No litigation, material capital-expenditure commitments, or off-balance-sheet arrangements were reported.
Most important facts to verify
- Confirm that this Original Source Entertainment filing is the intended filing; it does not identify NeuroOne Medical Technologies as the registrant.
- Verify the reported year-end cash, current liabilities, related-party advances, and the terms and status of the convertible note.
- Review the going-concern qualification and whether subsequent financing or operating developments changed the company’s ability to continue.
- Check whether the disclosed internal-control weaknesses were remediated and whether disclosure controls improved.
- Assess actual 2014 revenue sources and customer concentration; the filing’s concentration figures are historical and not clearly period-specific.